In this video, Jaideep S. Sohi, MD, explains factors to consider regarding the timing of re-imaging with PSMA-PET in patients with prostate cancer. "PSMA-PET is a radio nucleotide-based imaging ...

“The patients I find that have the most pronounced benefit are the patients with the very large prostates, or the patients who are catheter dependent with concern for neurogenic or myogenic bladder ...

Mona Lisa 2.0 receives CE certification, enabling use in 32 European countries for prostate cancer procedures. The platform offers advanced positioning and software for real-time adjustments, ...

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life ...

Data for newer therapies have shown that more than 50% of patients with BCG-unresponsive NMIBC experience a complete response after just 3 months of treatment. What are your thoughts on these findings ...

Johnson & Johnson seeks FDA approval for TAR-200, targeting BCG-unresponsive high-risk NMIBC with CIS, through the Real-Time Oncology Review program. Phase 2b SunRISe-1 trial data showed an 83.5% ...

"Just having someone with another set of eyes I think is always helpful and gives you a lot of inspiration as well as a lot of encouragement on exactly what you need to do next," says Gia Ching. In ...

"It was a daunting task, although I will say the original core was exceptional, so I had a wonderful framework from which to work," says Jeffrey A. Albaugh, PhD, APRN, CUCNS. In this video, Jeffrey A.

"I think integrating microbiome surveillance into clinical trials can bridge the gap between research and also therapeutic applications," says Ilaha Isali, MD, MSc. The abstract suggests that ...

How has the introduction of targeted gene therapy changed the way you approach managing BCG-unresponsive NMIBC? What are the broader implications of using gene therapy to treat BCG-unresponsive NMIBC, ...

The RELIEF ureteral stent is the first FDA-cleared stent for vesicoureteral reflux prevention in the US. The stent's design minimizes bladder spasms and reflux, improving patient comfort compared to ...

"The increasing expenses associated with bladder cancer treatment highlight wider issues regarding the sustainability of health care expenditures in the US," writes Michael S. Cookson, MD, MMHC, FACS.